Updated KEYTRUDA ® (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology
Dateline City:
KENILWORTH, N.J. Data from KEYNOTE-013 Demonstrated Overall Response Rate of 41 Percent, with 86 Percent of Responses Ongoing at the Time of AnalysisKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today study findings demonstrating that KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, achieved an overall
response rate (ORR) of 41 percent (n=7/17) (90% CI, 21-64) with
follow-up of up to 27 months in patients with relapsed or refractory
primary mediastinal large B-cell lymphoma (PMBCL), a type ...
Source: Merck.com - Product News - December 5, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK ASH Keytruda lymphoma MSD Source Type: news
New KEYTRUDA ® (pembrolizumab) Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies
Dateline City:
KENILWORTH, N.J. Findings to be Presented in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Malignant Pleural Mesothelioma with KEYTRUDA as Monotherapy and in Combination with Other Treatments Quality of Life Data from KEYNOTE-024 in First-Line Non-Small Cell Lung Cancer to be Presented in Plenary SessionKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data investigating the use of KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, across multiple
thoracic malignancies, in...
Source: Merck.com - Product News - November 30, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda NYSE:MRK Source Type: news
New KEYTRUDA ® (pembrolizumab) Data in Blood Cancers to be Presented at 58th Annual Meeting of the American Society of Hematology
Dateline City:
KENILWORTH, N.J. Updated Findings with Longer Follow-Up in Classical Hodgkin Lymphoma to be Featured in Oral PresentationsKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data regarding the investigational use of
KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy,
in patients with a range of blood cancers including classical Hodgkin
lymphoma and primary mediastinal large B-cell lymphoma, will be
presented at the 58th Annual Meeting of the American Society of
Hematology (ASH) in ...
Source: Merck.com - Product News - November 22, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #MRK $MRK Keytruda MDS Merck pembrolizamab Source Type: news
Merck ’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer
Dateline City:
KENILWORTH, N.J. First Presentation of Data from Phase 3 KEYNOTE-045 Study Presented at the Society for Immunotherapy of Cancer ’s (SITC) 31 st Annual MeetingKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from the pivotal KEYNOTE-045 study investigating
the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, in patients with advanced bladder (urothelial) cancer
previously treated with platinum-containing chemotherapy. As previously
announced, KEYTRUDA was superior to i...
Source: Merck.com - Product News - November 12, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news
New KEYTRUDA ® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting
Dateline City:
KENILWORTH, N.J. First Presentation of Overall Survival Data in Patients with Advanced Bladder (Urothelial) Cancer from KEYNOTE-045 StudyKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that new data investigating the use of KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, in patients with
previously treated advanced urothelial cancer will be presented at the
Society for Immunotherapy of Cancer’s (SITC) 31st Annual
Meeting, Nov. 9-13.Language:
EnglishContact: MerckMedia:Pa...
Source: Merck.com - Product News - November 7, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD SITC Source Type: news
FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations
Dateline City:
KENILWORTH, N.J. KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA...
Source: Merck.com - Product News - October 24, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda Source Type: news
Merck ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early
Dateline City:
KENILWORTH, N.J. KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival Compared With Chemotherapy in Urothelial CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the phase 3 KEYNOTE-045 trial investigating the use
of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, in patients with previously treated advanced urothelial cancer,
met the primary endpoint of overall survival (OS). In this trial,
KEYTRUDA was superior compared to investigator choice chemotherapy.Lang...
Source: Merck.com - Product News - October 21, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news
Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck ’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients
Dateline City:
KENILWORTH, N.J. KEYNOTE-024, Published in The New England Journal of Medicine, Showed KEYTRUDA as Monotherapy Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with High Levels of PD-L1 Expression KEYNOTE-021, Cohort G, Published in The Lancet Oncology, Showed KEYTRUDA in Combination with Chemotherapy Demonstrated Superior Efficacy Compared to Chemotherapy Alone as First-Line Treatment; Trial Enrolled Patients Regardless of PD-L1 ExpressionKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD...
Source: Merck.com - Product News - October 9, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer ESMO Keytruda MSD NYSE:MRK Source Type: news
KEYTRUDA ® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress
Dateline City:
KENILWORTH, N.J. Results from KEYNOTE-010 Include Improved Patient-Reported Health-Related Quality of Life Outcomes and 18-Month Findings of Overall Survival and Progression-Free Survival in Previously Treated Patients Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or More)
KENILWORTH, N.J.--(BUSINESS WIRE)--
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that KEYTRUDA® (pembrolizumab), the company ’s
anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at
18 months compared to standard of care...
Source: Merck.com - Product News - October 9, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer ESMO Keytruda MSD NYSE:MRK Source Type: news
Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA ® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress
Dateline City:
KENILWORTH, N.J. Data Comparing KEYTRUDA to Chemotherapy Shows Continued Benefit with Follow-Up Beyond 2.5 Years in Patients with Ipilimumab-Refractory Advanced MelanomaKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced findings from the final overall survival (OS) analysis
from the KEYNOTE-002 study investigating the use of KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, compared to
investigator-choice chemotherapy with a crossover to KEYTRUDA design, in
patients with ipilimumab-refr...
Source: Merck.com - Product News - October 8, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Melanoma MSD Source Type: news
New KEYTRUDA ® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients
Dateline City:
KENILWORTH, N.J. Results from Interim Analysis of Phase 2 KEYNOTE-052 Study to be Presented at ESMO 2016 Congress and Highlighted in ESMO Press Program First Presentation of Data Investigating KEYTRUDA in the Front Line Treatment of Bladder CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced positive findings from the phase 2 KEYNOTE-052 study
investigating the use of KEYTRUDA® (pembrolizumab), the
company ’s anti-PD-1 therapy, in previously untreated patients with
unresectable (inoperable) or m...
Source: Merck.com - Product News - October 8, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news
FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck ’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Dateline City:
KENILWORTH, N.J. Merck Has Also Submitted a Marketing Authorization Application to the European Medicines Agency for KEYTRUDA in the Same Patient Population Submissions Based on Data from KEYNOTE-024 Trial Showing Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Express High Levels of PD-L1KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for Priority Review the supplemental Biologics License
Ap...
Source: Merck.com - Product News - September 7, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news
Results from Merck ’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the publication of results fromC-EDGE
CO-STAR.C-EDGE CO-STAR is a Phase 3 trial evaluating the
use of ZEPATIER ™ (elbasvir and grazoprevir) 50mg/100mg tablets in
patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6
infection receiving opioid agonist therapy (OAT) (methadone and
buprenorphine), commonly used to treat opioid addiction.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orSarra ...
Source: Merck.com - Product News - August 8, 2016 Category: Drugs & Pharmacology Tags: Hepatitis C Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK Annals of Internal Medicine MSD ZEPATIER Source Type: news
FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA®(pembrolizumab), the company ’s anti-PD-1
(programmed death receptor-1) therapy, at a fixed dose of 200 mg every
three weeks, for the treatment of patients with recurrent or metastatic
head and neck squamous cell carcinoma (HNSCC) with disease progression
on or after platinum-containing chemotherap y.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-...
Source: Merck.com - Product News - August 8, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
